Literature DB >> 22822307

Venous thromboembolic disease.

Michael R Jaff1.   

Abstract

Physicians understand the importance of prompt diagnosis and therapy of venous thromboembolism. This is a common and potentially deadly disease. Many patients may have no symptoms of this disorder, yet face a significant risk of serious complications if undiagnosed and untreated. Venous duplex ultrasonography has become the diagnostic test of choice for deep venous thrombosis. Quantitative d-dimer levels may be very helpful in establishing the diagnosis of venous thrombosis. Helical (spiral) computed tomographic scans have replaced nuclear medicine ventilation-perfusion imaging for pulmonary embolus. So, the evolution of diagnostic methods has helped to identify patients with venous thromboembolism at an earlier stage of the disease. Treatment of venous thromboembolism has rapidly evolved over the past 40 years. Patients are often treated with subcutaneous low-molecular-weight heparins as outpatients, rather than admitted to hospital for continuous intravenous infusions of unfractionated heparin. This change in practice grew from a body of scientific literature supporting this advance.

Entities:  

Year:  2002        PMID: 22822307      PMCID: PMC3399237     

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  15 in total

1.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

Authors:  D W BARRITT; S C JORDAN
Journal:  Lancet       Date:  1960-06-18       Impact factor: 79.321

2.  A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.

Authors:  F A Anderson; H B Wheeler; R J Goldberg; D W Hosmer; N A Patwardhan; B Jovanovic; A Forcier; J E Dalen
Journal:  Arch Intern Med       Date:  1991-05

3.  Incidence of venous thromboembolism verified by necropsy over 30 years.

Authors:  B Lindblad; N H Sternby; D Bergqvist
Journal:  BMJ       Date:  1991-03-23

4.  Pulmonary embolism thrombolysis: a clarion call for international collaboration.

Authors:  S Z Goldhaber
Journal:  J Am Coll Cardiol       Date:  1992-02       Impact factor: 24.094

Review 5.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

Authors:  J Hirsh; J E Dalen; D R Anderson; L Poller; H Bussey; J Ansell; D Deykin; J T Brandt
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

Review 6.  Low-molecular-weight heparins.

Authors:  J I Weitz
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

7.  Incidence of venous thromboembolism in hospitalized patients vs community residents.

Authors:  J A Heit; L J Melton; C M Lohse; T M Petterson; M D Silverstein; D N Mohr; W M O'Fallon
Journal:  Mayo Clin Proc       Date:  2001-11       Impact factor: 7.616

8.  The long-term clinical course of acute deep venous thrombosis.

Authors:  P Prandoni; A W Lensing; A Cogo; S Cuppini; S Villalta; M Carta; A M Cattelan; P Polistena; E Bernardi; M H Prins
Journal:  Ann Intern Med       Date:  1996-07-01       Impact factor: 25.391

9.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

10.  Acquired risk factors for deep-vein thrombosis in symptomatic outpatients.

Authors:  A Cogo; E Bernardi; P Prandoni; B Girolami; F Noventa; P Simioni; A Girolami
Journal:  Arch Intern Med       Date:  1994-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.